Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/08/2023* 08:30 EST Earnings Call Q4 2022 -- -- --
02/08/2023* -- Results Q4 2022 -- 0.58 --
11/01/2022 08:30 EST Earnings Call Q3 2022 -- -- --
11/01/2022 -- Results Q3 2022 0.77 0.68 13.23%
08/02/2022 08:30 EST Earnings Call Q2 2022 -- -- --
08/02/2022 -- Results Q2 2022 0.91 0.71 27.44%
05/03/2022 08:30 EST Earnings Call Q1 2022 -- -- --
05/03/2022 -- Results Q1 2022 0.92 0.72 27.72%
*Estimated Date/Time

Earnings

Next Report Date 02/08/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/01/2022
Beat/Miss Upgrade
Return Since -3.62%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
URL https://www.repligen.com
Investor Relations URL https://www.repligen.com/company/investors
HQ State/Province Massachusetts
Sector Healthcare
Industry Medical Instruments & Supplies
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 08, 2023 (est.)
Last Earnings Release Nov. 01, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
42.88%
8.94%
17.72%
45.37%
75.39%
107.2%
38.20%
-32.47%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.10%
-9.75%
-7.43%
21.96%
-5.54%
-1.39%
-17.48%
-2.02%
27.20%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
44.08%
103.8%
-6.28%
34.76%
-0.90%
-23.15%
-4.64%
55.31%
-52.80%
--
--
46.61%
-28.98%
7.47%
270.8%
117.4%
-56.48%
As of November 30, 2022.

Profile

Edit
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
URL https://www.repligen.com
Investor Relations URL https://www.repligen.com/company/investors
HQ State/Province Massachusetts
Sector Healthcare
Industry Medical Instruments & Supplies
Equity Style Mid Cap/Growth
Next Earnings Release Feb. 08, 2023 (est.)
Last Earnings Release Nov. 01, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
BCSIX 176.61M USD 4.76%
PBE 9.600M USD 3.73%
BIGZ 50.47M USD 2.40%
DMCFX 107.05M USD 2.01%
TRUZX 447.13M USD 1.96%
HMDCX 103.21M USD 1.41%
FDTRX 187.11M USD 1.12%
MDYG 17.66M USD 0.87%
IJK 61.53M USD 0.87%
IBB 70.86M USD 0.82%
VISGX 151.49M USD 0.54%
VBK 151.49M USD 0.54%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter RGEN Tweets